Aristotle Capital Boston LLC Has $11.66 Million Stock Holdings in Supernus Pharmaceuticals, Inc. $SUPN

Aristotle Capital Boston LLC cut its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 23.2% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 234,503 shares of the specialty pharmaceutical company’s stock after selling 70,770 shares during the quarter. Aristotle Capital Boston LLC’s holdings in Supernus Pharmaceuticals were worth $11,655,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. State Street Corp increased its stake in shares of Supernus Pharmaceuticals by 1.4% in the fourth quarter. State Street Corp now owns 2,219,228 shares of the specialty pharmaceutical company’s stock valued at $110,296,000 after buying an additional 31,668 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Supernus Pharmaceuticals by 4.5% in the fourth quarter. Geode Capital Management LLC now owns 1,472,899 shares of the specialty pharmaceutical company’s stock valued at $73,215,000 after buying an additional 62,875 shares in the last quarter. Loomis Sayles & Co. L P increased its stake in shares of Supernus Pharmaceuticals by 12.7% in the fourth quarter. Loomis Sayles & Co. L P now owns 1,448,842 shares of the specialty pharmaceutical company’s stock valued at $72,007,000 after buying an additional 162,905 shares in the last quarter. Stephens Investment Management Group LLC increased its stake in shares of Supernus Pharmaceuticals by 4.5% in the fourth quarter. Stephens Investment Management Group LLC now owns 1,406,522 shares of the specialty pharmaceutical company’s stock valued at $69,904,000 after buying an additional 61,120 shares in the last quarter. Finally, Woodline Partners LP increased its stake in shares of Supernus Pharmaceuticals by 63.5% in the third quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company’s stock valued at $60,398,000 after buying an additional 490,835 shares in the last quarter.

Analysts Set New Price Targets

A number of analysts recently commented on SUPN shares. Zacks Research upgraded Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Craig Hallum set a $65.00 price objective on Supernus Pharmaceuticals in a research report on Wednesday, February 25th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Friday, March 27th. Finally, Wall Street Zen lowered Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 23rd. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Supernus Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $62.17.

Supernus Pharmaceuticals Price Performance

Shares of SUPN stock opened at $43.58 on Thursday. The firm has a market cap of $2.53 billion, a price-to-earnings ratio of -85.45, a PEG ratio of 0.93 and a beta of 0.55. Supernus Pharmaceuticals, Inc. has a 12 month low of $30.83 and a 12 month high of $59.68. The stock has a 50-day moving average price of $48.27 and a 200 day moving average price of $49.51.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained?release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended?release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended?release capsules), approved for the treatment of attention?deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.